Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Exelixis Inc 1851 Harbor Bay Parkway Alameda CA 94502 USA

www.exelixis.com Employees: 1,077 P: 650-837-7000 F: 650-837-8300

Sector:

Medical

Description:

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Key Statistics

Overview:

Market Capitalization, $K 10,894,794
Enterprise Value, $K 10,412,304
Shares Outstanding, K 259,709
Float, K 252,307
% Float 97.15%
Short Interest, K 26,353
Short Float 10.15%
Days to Cover 7.37
Short Volume Ratio 0.46
% of Insider Shareholders 2.85%
% of Institutional Shareholders 85.27%

Financials:

Annual Sales, $ 2,320 M
Annual Net Income, $ 782,570 K
Last Quarter Sales, $ 598,660 K
Last Quarter Net Income, $ 244,530 K
EBIT, $ 872,200 K
EBITDA, $ 901,260 K

Growth:

1-Year Return 16.38%
3-Year Return 104.83%
5-Year Return 81.44%
5-Year Revenue Growth 134.94%
5-Year Earnings Growth 694.29%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.94 on 02/10/26
Next Earnings Date 05/12/26
Earnings Per Share ttm 2.73
EPS Growth vs. Prev Qtr 31.34%
EPS Growth vs. Prev Year 83.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

EXEL Ratios

Ratio
Price/Earnings ttm 15.21
Price/Earnings forward 13.55
Price/Earnings to Growth 0.93
Return-on-Equity % 36.29%
Return-on-Assets % 27.54%
Profit Margin % 33.73%
Debt/Equity 0.00
Price/Sales 4.65
Price/Cash Flow 13.72
Price/Book 5.15
Book Value/Share 8.06
Interest Coverage 2.75
60-Month Beta 0.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.